TNF receptors, TNF binding proteins and DNAs coding for them

- Amgen Boulder Inc.

DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.

Skip to:  ·  Claims  ·  References Cited  · Patent History  ·  Patent History

Claims

1. A method for the detection of TNF in a biological sample, comprising contacting said sample with an effective amount of a recombinant polypeptide comprising the amino acid sequence, ##STR11## or a fragment, variant, or functional derivative thereof which binds to TNF, and detecting whether a complex is formed.

Referenced Cited
Other references
  • Carlino, J.A., et al., J. Biol. Chem., vol. 262, No. 3, pp. 958-961, Jan. 25, 1987. Stauber, G.B., et al., J. Biol. Chem. , vol. 263, No. 35. pp. 19098-19104, Dec. 15, 1988.
Patent History
Patent number: 5843791
Type: Grant
Filed: Jun 7, 1995
Date of Patent: Dec 1, 1998
Assignee: Amgen Boulder Inc. (Boulder, CO)
Inventors: Rudolf Hauptmann (Ebreichsdorf), Adolf Himmler (Vienna), Ingrid Maurer-Fogy (Lindauergasse), Christian Stratowa (Vienna)
Primary Examiner: Toni R. Scheiner
Law Firm: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
Application Number: 8/477,639
Classifications
Current U.S. Class: Biospecific Ligand Binding Assay (436/501); 435/723; Utilizing Isolate Of Tissue Or Organ As Binding Agent (436/503); Cancer (436/64)
International Classification: G01N 3353; G01N 33574;